Twentyeight Health vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
Twentyeight Health provides affordable telehealth and mail-order pharmacy for contraception, STI testing, and reproductive health to underserved and low-income women.
About
Twentyeight Health is a reproductive health telehealth company founded in 2019 that focuses specifically on expanding access to contraception and reproductive healthcare for underserved women, including those on Medicaid, without insurance, or in rural areas. The platform provides online consultations with licensed providers for birth control prescriptions, STI testing kits by mail, emergency contraception, and general reproductive health questions at accessible price points with Medicaid acceptance. Twentyeight raised $25M and has enrolled hundreds of thousands of patients, with a focus on the communities most affected by reproductive healthcare access gaps. The company differentiates from other telehealth platforms by prioritizing Medicaid acceptance, multilingual care, and a health equity mission rather than serving primarily the commercially insured population. Twentyeight operates in most US states and has built relationships with state health departments and safety-net healthcare organizations. As access to reproductive healthcare has become more constrained in some US states, Twentyeight's telehealth model has become an increasingly critical access point for patients who cannot easily reach in-person reproductive health services.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.